Accuray Incorporated Stock price

Equities

ARAY

US0043971052

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.47 USD +1.65% Intraday chart for Accuray Incorporated -2.76% -12.72%
Sales 2024 * 462M Sales 2025 * 489M Capitalization 245M
Net income 2024 * -8M Net income 2025 * 13M EV / Sales 2024 * 0.53 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.5 x
P/E ratio 2024 *
-29.9 x
P/E ratio 2025 *
18.5 x
Employees 1,024
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.25%
More Fundamentals * Assessed data
Dynamic Chart
Accuray Incorporated Announces New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can Be Effectively Treated in 5 Days Using the Accuray CyberKnife System CI
Roth MKM Starts Accuray With Buy Rating, $9 Price Target MT
Quebec Cancer Center Is First in Canada to Treat Cancer Patients Using the Accuray Radixact System CI
Transcript : Accuray Incorporated, Q2 2024 Earnings Call, Jan 31, 2024
Earnings Flash (ARAY) ACCURAY INCORPORATED Posts Q2 Revenue $107.2M, vs. Street Est of $106.7M MT
Accuray Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Accuray Incorporated Reaffirms Revenue Guidance for the Third Quarter and Full Fiscal Year 2024 CI
Accuray Incorporated Announces the Providence Swedish Radiosurgery Center in Seattle Invests in Second Accuray Cyberknife System CI
Accuray Insider Sold Shares Worth $161,624, According to a Recent SEC Filing MT
B. Riley Trims Accuray's Price Target to $6.50 From $7.50 on Lower Multiple, Maintains Buy Rating MT
Transcript : Accuray Incorporated, Q1 2024 Earnings Call, Nov 07, 2023
Accuray Incorporated Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Earnings Flash (ARAY) ACCURAY INCORPORATED Reports Q1 Revenue $103.9M, vs. Street Est of $97.6M MT
Accuray Shares Rise After Securing Approval for Tomo C Radiation Therapy System in China MT
Accuray Secures Approval for Tomo C Radiation Therapy System in China MT
More news
1 day+1.65%
1 week-5.00%
Current month-5.00%
1 month-8.86%
3 months-17.94%
6 months-9.52%
Current year-12.72%
More quotes
1 week
2.37
Extreme 2.37
2.56
1 month
2.37
Extreme 2.37
2.95
Current year
2.36
Extreme 2.36
2.99
1 year
2.36
Extreme 2.36
4.30
3 years
1.70
Extreme 1.7
5.93
5 years
1.33
Extreme 1.33
6.02
10 years
1.33
Extreme 1.33
10.01
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 19-10-20
Director of Finance/CFO 44 20-07-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 64 18-01-06
Director/Board Member 60 23-01-29
Chief Executive Officer 61 19-10-20
More insiders
Date Price Change Volume
24-03-28 2.47 +1.65% 423,711
24-03-27 2.43 +2.53% 607,358
24-03-26 2.37 -4.44% 1,146,176
24-03-25 2.48 -0.40% 433,603
24-03-22 2.49 -1.97% 311,325

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells, and supports solutions that are designed to deliver radiation treatments. Its solutions are designed to advance patient care during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, the Company also provides services, which include post-contract customer support (warranty period services and post warranty services), installation services, training, and other professional services.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.47 USD
Average target price
8.75 USD
Spread / Average Target
+254.25%
Consensus
  1. Stock
  2. Equities
  3. Stock Accuray Incorporated - Nasdaq